AstraZeneca drops early head and neck cancer drug plans

LONDON, Nov 10 (Reuters) - AstraZeneca said on

Thursday it had given up on the idea of seeking an early

approval of its immunotherapy drug durvalumab in head and neck

cancer using mid-stage Phase II...

Read more